Research Library
PT-141 research
6 articles to explore, with links to 5 original sources.
About PT-141
PT-141, also known as bremelanotide, is a cyclic peptide used in melanocortin receptor research.
Understand the science
What a Receptor Structure Can Explain About PT-141
Bremelanotide, also called PT-141, is a cyclic peptide in the melanocortin research family. The current US label describes it as a melanocortin receptor agonist.
2 sources (2021, 2026)
Explore study findings
What Participants Reported After the Bremelanotide Trials
Bremelanotide, also called PT-141, was evaluated in the RECONNECT trials for hypoactive sexual desire disorder. An older exit-study report examined what some trial participants said about their experience.
2 sources (2021, 2026)
Check methods and identity
What the Current US Bremelanotide Label Covers
PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.
1 source (2026)
How Two Phase 3 Trials Measured Desire and Distress Separately
Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.
2 sources (2019, 2026)
What the 2026 Bremelanotide Label Reports About Safety
PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.
1 source (2026)
Interpret the evidence
Why the Bremelanotide Extension Study Cannot Replace a Placebo Comparison
PT-141, or bremelanotide, had a 52-week extension after the controlled phase of the RECONNECT studies. The older extension is the direct source for this comparison of study designs. Its results should be read alongside the current US labeling.
2 sources (2019, 2026)
